MDS Pharma Services Upgrades, Expands Singapore Global Central Laboratory Operation
16 Ottobre 2008 - 2:00PM
PR Newswire (US)
New facility creates greater efficiencies to better meet client
needs KING OF PRUSSIA, PA, Oct. 16 /PRNewswire-FirstCall/ -- MDS
Pharma Services, a leading provider of innovative drug-discovery
and development solutions, today announced it has moved its
Singapore Global Central Lab operation to a new, larger facility,
enabling the contract research organization to better meet the
current and emerging needs of its clients in the Asia-Pacific
region. Thanks to optimized layout and workflow, the new facility,
which is located in the Marsiling Industrial Park, has twice its
previous capacity for sample storage, processing, and safety
testing. Increased capacity was required to handle both current
sample volumes - MDS Pharma Services has seen its sample volume in
Singapore double in the past year - and to meet anticipated
increases in business as a result of growing research investment in
the area. "MDS Pharma Services has long recognized the importance
of investing in the Asia-Pacific region, and our move to a new
laboratory facility in Singapore - which is becoming a hub of
drug-development activity - is a testament to our commitment to
growing across Asia," says MDS Pharma Services President David
Spaight. "We were the first Western contract research organization
to own a facility in China, and the first clinical laboratory there
to receive accreditation from the College of American Pathologists
(CAP). MDS Pharma Services remains at the forefront of the industry
with the resources, expertise and commitment to deliver Quality
On-Time(TM) services for clients in Singapore and the entire
Asia-Pacific region." The Singapore central lab has earned National
Glycohemoglobin Standardization Program (NGSP) Level 1
accreditation, which allows it to handle diabetes studies conducted
under strict international guidelines. It has also earned CAP
accreditation, and recently passed its CAP inspection with zero
deficiencies. The move further solidifies MDS Pharma Services
presence in the Asia-Pacific region, an area with increasing
importance in the drug-development industry. Since entering the
region over a decade ago, MDS Pharma Services has built a strong
staff of clinical development professionals with expertise in many
areas. In addition to central lab services, the Singapore facility
is one of its two Asia-Pacific sites - the other is Beijing, China
- through which MDS Pharma Services offers its industry-leading
integrated centralized cardiac safety services to the entire
region. Singapore is also one of MDS Pharma Services' eight Asian
Global Clinical Development sites that offer late-stage clinical
trial monitoring. MDS Pharma Services offers pharmacology services
from its Taipei, Taiwan location. MDS Pharma Services provides
central laboratory services in key geographic areas around the
world, including Singapore, China, Canada, the United States,
France and Germany. About MDS Pharma Services MDS Pharma Services
is committed to delivering quality service on time. We offer a full
spectrum of resources to meet the drug discovery and development
needs of the pharmaceutical and biotechnology industries. With
numerous facilities strategically located around the world, we
apply advanced scientific and technological expertise throughout
the drug discovery and development process - from lead
optimization, pre-IND research, early clinical research
(bioequivalence, phases I-IIa) and bioanalysis through to global
clinical development (phases IIb-IV), central lab and centralized
cardiac services. For more information, visit our website at
http://www.mdsps.com/. MDS Pharma Services is a business unit of
MDS Inc. (TSX: MDS; NYSE: MDZ), a global life sciences company that
provides market-leading products and services that our customers
need for the development of drugs and diagnosis and treatment of
disease. We are a leading global provider of pharmaceutical
contract research, medical isotopes for molecular imaging,
radiotherapeutics, and analytical instruments. MDS has more than
5,500 highly skilled people in 29 countries. Find out more at
http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24 hours a
day. DATASOURCE: MDS Inc. CONTACT: For Media: Charlene McGrady,
(610) 239-7900 ext. 231, ; For Investors: Kim Lee, (416) 213-4721,
Copyright